文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Multiple microtubule alterations are associated with Vinca alkaloid resistance in human leukemia cells.

作者信息

Kavallaris M, Tait A S, Walsh B J, He L, Horwitz S B, Norris M D, Haber M

机构信息

Children's Cancer Institute Australia for Medical Research, High Street, Randwick, NSW, Australia 2031.

出版信息

Cancer Res. 2001 Aug 1;61(15):5803-9.


DOI:
PMID:11479219
Abstract

Vinca alkaloids are used extensively in the treatment of childhood acute lymphoblastic leukemia (ALL) and despite their usefulness, drug resistance remains a serious clinical problem. Vinca alkaloids bind to the beta-tubulin subunit of the alpha/beta-tubulin heterodimer and inhibit polymerization of microtubules. Recent studies have implicated altered beta-tubulin isotype expression and mutations in resistance to microtubule-stabilizing agents. Microtubule-associated protein (MAP) MAP4 binds to and stabilizes microtubules, and increased expression is associated with decreased sensitivity to microtubule-depolymerizing agents. To address the significance of beta-tubulin and MAP4 alterations in childhood ALL, two CCRF-CEM-derived Vinca alkaloid resistant cell lines, VCR R (vincristine) and VLB100 (vinblastine), were examined. Decreased expression of class III beta-tubulin was detected in both VCR R and VLB100 cells. VCR R cells and to a lesser extent VLB100 cells expressed increased levels of MAP4 protein. Increased microtubule stability was observed in these VCR R cells as identified by the high levels of polymerized tubulin (45.6 +/- 2.6%; P < 0.005) compared with CEM and VLB100 cells (24.7 +/- 3.3% and 24.7 +/- 2.5%, respectively). Expression was associated with a single MAP4 isoform in the polymerized microtubule fraction in CEM and VCR cells. In contrast, VLB100 cells expressed a lower molecular weight isoform in the polymerized fraction. Two-dimensional-PAGE and immunoblotting revealed marked posttranslational changes in class I beta-tubulin in VCR R cells not evident in CEM cells. Sequencing of the beta-tubulin (HM40) gene identified a point mutation in VCR R cells in nucleotide 843 (CTC-->ATC; Leu(240)-->Ile) that was not present in CEM or VLB100 cells. This mutation resides in a region of beta-tubulin that lies in close proximity to the alpha/beta tubulin interface. Multiple alterations related to normal microtubule function were identified in ALL cells selected for resistance to Vinca alkaloids, and these alterations may provide important insight into mechanisms mediating resistance to Vinca alkaloids.

摘要

相似文献

[1]
Multiple microtubule alterations are associated with Vinca alkaloid resistance in human leukemia cells.

Cancer Res. 2001-8-1

[2]
Proteome analysis of vinca alkaloid response and resistance in acute lymphoblastic leukemia reveals novel cytoskeletal alterations.

J Biol Chem. 2003-11-14

[3]
Alterations in gamma-actin and tubulin-targeted drug resistance in childhood leukemia.

J Natl Cancer Inst. 2006-10-4

[4]
DNA damage increases sensitivity to vinca alkaloids and decreases sensitivity to taxanes through p53-dependent repression of microtubule-associated protein 4.

Cancer Res. 1999-8-1

[5]
Resistance to apoptotic cell death in a drug resistant T cell leukaemia cell line.

Leukemia. 1996-3

[6]
Neuronal-associated microtubule proteins class III beta-tubulin and MAP2c in neuroblastoma: role in resistance to microtubule-targeted drugs.

Mol Cancer Ther. 2004-9

[7]
Resistance to microtubule-targeted cytotoxins in a K562 leukemia cell variant associated with altered tubulin expression and polymerization.

Bull Cancer. 2004-5

[8]
Reversal of Vinca alkaloid resistance but not multiple drug resistance in human leukemic cells by verapamil.

Cancer Res. 1986-2

[9]
Elevated levels of microtubule destabilizing factors in a Taxol-resistant/dependent A549 cell line with an alpha-tubulin mutation.

Cancer Res. 2003-3-15

[10]
Mutations in alpha- and beta-tubulin that stabilize microtubules and confer resistance to colcemid and vinblastine.

Mol Cancer Ther. 2003-7

引用本文的文献

[1]
Comparative Analysis of Chemotherapy Resistance Mechanisms in Humans and Companion Animals.

Vet Sci. 2025-8-12

[2]
Herbal Therapies for Cancer Treatment: A Review of Phytotherapeutic Efficacy.

Biologics. 2024-9-10

[3]
Tubulin Complexity in Cancer and Metastasis.

Adv Exp Med Biol. 2024

[4]
Exploring the mechanism of resistance to vincristine in breast cancer cells using transcriptome sequencing technology.

Oncol Lett. 2023-10-5

[5]
Discovery of potent tubulin inhibitors targeting the colchicine binding site via structure-based lead optimization and antitumor evaluation.

J Enzyme Inhib Med Chem. 2023-12

[6]
Cellular and Molecular Effects of Eribulin in Preclinical Models of Hematologic Neoplasms.

Cancers (Basel). 2022-12-10

[7]
Design, Synthesis and Biological Investigation of 2-Anilino Triazolopyrimidines as Tubulin Polymerization Inhibitors with Anticancer Activities.

Pharmaceuticals (Basel). 2022-8-21

[8]
PI3K/AKT Signaling Tips the Balance of Cytoskeletal Forces for Cancer Progression.

Cancers (Basel). 2022-3-24

[9]
Inhibition of Microtubule Dynamics in Cancer Cells by Indole-Modified Latonduine Derivatives and Their Metal Complexes.

Inorg Chem. 2022-1-24

[10]
Nano-Based Drug Delivery and Targeting to Overcome Drug Resistance of Ovarian Cancers.

Cancers (Basel). 2021-10-31

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索